Filing Flows › Ultragenyx Pharmaceutical (RARE) › Q2 2026 › vs Q2 2025
Ultragenyx Pharmaceutical (RARE) Q2 2026 vs Q2 2025 (year over year)
Ultragenyx Pharmaceutical's revenue rose $47.0M (+28%) from $167M in Q2 2025 to $214M in Q2 2026. The biggest changes: Product +$31.0M (+38%); Royalty +$16.0M (+19%).
Ultragenyx Pharmaceutical, Q2 2026: revenue $214M (+28% year over year), operating margin -35.0%, net loss $92.0M, operating cash flow −$97.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $112M | $81.0M | $31.0M | +38% |
| Royalty | $102M | $86.0M | $16.0M | +19% |
| Revenue | $214M | $167M | $47.0M | +28% |
| Net loss | $92.0M | $115M | −$23.0M | -20% |
| Costs & expenses | $306M | $282M | $24.0M | +9% |
| Operating costs | $289M | $275M | $14.0M | +5% |
| Interest & other, net | $16.0M | $6.0M | $10.0M | +167% |
| Income tax | $1.0M | $1.0M | $0 | 0% |
| Research & development | $167M | $165M | $2.0M | +1% |
| SG&A | $88.0M | $87.0M | $1.0M | +1% |
| Other operating costs | $34.0M | $23.0M | $11.0M | +48% |
| Operating cash sources | $139M | $157M | −$18.0M | -11% |
| Depreciation & amortization | $8.0M | $9.0M | −$1.0M | -11% |
| Share-based compensation | $34.0M | $39.0M | −$5.0M | -13% |
| Cash used in operations | $97.0M | $109M | −$12.0M | -11% |
| Net loss absorbed | $92.0M | $115M | −$23.0M | -20% |
| Working capital & other | $47.0M | $42.0M | $5.0M | +12% |
Questions
How much did Ultragenyx Pharmaceutical's revenue grow year over year in Q2 2026?
Ultragenyx Pharmaceutical's revenue rose $47.0M (+28%) from $167M in Q2 2025 to $214M in Q2 2026.
What drove Ultragenyx Pharmaceutical's revenue change in Q2 2026?
Product +$31.0M (+38%); Royalty +$16.0M (+19%).